News
People with critical cardiovascular disease may benefit from palliative care

Palliative care may help relieve symptoms and improve quality of life for people with cardiovascular disease and ensure that treatment is aligned with the patient’s personal beliefs and values throughout all stages of illness, according to a new American Heart Association scientific statement.
This applies whether they are hospitalised in a cardiac intensive care unit or receiving outpatient care, says the statement.
The new scientific statement, “Palliative and End-of-Life Care During Critical Cardiovascular Illness,” suggests strategies to integrate palliative care principles into the management of patients with critical cardiovascular illness.
Palliative care aims to improve quality of life; to minimise physical, emotional and spiritual distress; to facilitate complex discussions regarding prognosis and goals of care; and to provide emotional and psychosocial support to patients, family members and caregivers throughout all stages of illness, not just at the end of life.
Currently, palliative care is most widely used caring for patients with cancer.
“We need to better understand the benefits of palliative care in a broad range of cardiovascular conditions and particularly for patients with acute, critical illness,” said volunteer Chair of the scientific statement writing group Erin Bohula, an assistant professor of medicine at Harvard Medical School and critical care cardiologist at Brigham & Women’s Hospital, both in Boston.
“People with a variety of heart conditions face increasing symptoms, functional limitations and a need to align care with their personal preferences, beliefs and values – whether that’s to do everything possible or to prioritise comfort and quality of life. A patient-centred approach needs to be considered, particularly when making decisions about available and sometimes invasive care options as their condition advances.”
The statement authors emphasise that palliative care can be provided in addition to evidence-based treatments at any stage of a person’s illness, from intensive care to outpatient care.
However, providing palliative care for cardiovascular disease can be challenging because the progression of the illness can be unpredictable, and there may be sudden, urgent situations requiring hospitalisation and/or admission to the cardiac intensive care unit.
These can result in new symptoms such as loss in physical function and may lead to unexpected end-of-life situations that necessitate more intensive support from cardiology and palliative care professionals.
In addition, many patients admitted to cardiac intensive care units are older (with a median age of 65 years), more frail and critically ill, with advanced and complex cardiovascular conditions, and they may also have multiple non-cardiac conditions.
Palliative care health professionals need to be knowledgeable about the medical prognosis and quick decision-making required in cardiac intensive care units, including the management of life-sustaining technologies and advanced cardiac interventions.
Palliative care can be integrated into care to manage symptoms and improve quality of life for patients with different types of cardiovascular disease, says the statement.
Despite the growing evidence about the benefits of palliative care, many people with cardiovascular disease have limited access to palliative care specialists. Rates of referral to palliative care for patients with cardiovascular disease are low and often delayed compared to patients with cancer.
Due to delayed referrals and the scarcity of palliative care resources, it can be difficult for individuals with cardiovascular disease to access outpatient palliative care. Inpatient palliative care services may also be limited in settings outside of large hospitals.
The statement suggests integrating palliative care services into heart failure clinics and post-discharge services for patients recently hospitalised in the cardiac intensive care unit, creating a transition from inpatient to outpatient care.
There are also complex ethical considerations for patients with advanced cardiovascular disease, particularly in relation to life-sustaining interventions.
Medical codes of ethics emphasise promoting patient well-being, avoiding harm and respecting patient autonomy; however, these can sometimes seem at odds in the setting of the cardiac intensive care unit or treating a patient with end-stage cardiovascular disease.
For example, deactivating the shocking function of an implanted cardiac defibrillator may increase the risk of death if a fatal arrhythmia occurs, while at the same time minimising a patient’s pain by avoiding the delivery of multiple shocks.
A separate, recently published American Heart Association scientific statement on palliative care and advanced cardiovascular disease highlights the importance of shared decision-making involving the patient and family as the disease progresses.
When a patient’s symptoms become more severe and difficult to manage, discussions about changing or discontinuing certain treatments may be necessary based on the patient’s personal preferences, quality of life, prognosis and advanced care documents.
Education for cardiovascular specialists
While palliative care is not a recognised subspecialty of cardiology, its approaches can be offered by cardiovascular clinicians with specialized training in palliative care and in consultation with palliative care specialists. However, only a small fraction of health care professionals who complete a cardiology fellowship receive either required or elective training in palliative care.
The scientific statement also identifies several basic palliative care.
“It is critical that all cardiac intensive care unit and acute care professionals have the tools and knowledge to provide the basic tenets of palliative care, such as symptom management and ensuring that care is appropriate and aligns with the patient’s personal choices. As the field of cardiac critical care advances, incorporating palliative care principles ensures a holistic approach to providing care and addressing the complex needs of these patients during a health care crisis or at the end-of-life,” said Bohula.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








